Table 5.
Univariate and multivariate logistic regression analyses of PSCI at 1 year.
| Characteristics (n = 55) | Crude OR (95% CI) | P-value | Adjusted OR† (95% CI) | P-value |
|---|---|---|---|---|
| Age | 1.05 (0.98–1.13) | 0.164 | ||
| Male sex | 1.29 (0.24–7.02) | 0.765 | ||
| Education level (year) | 0.86 (0.72–1.02) | 0.092 | ||
| Hypertension | 0.70 (0.18–2.78) | 0.616 | ||
| Diabetes mellitus | 2.10 (0.60–7.40) | 0.248 | ||
| Hemoglobin A1c (%) ≤ 7 days | 1.02 (0.72–1.44) | 0.921 | ||
| Hyperlipidemia | 1.67 (0.39–7.04) | 0.487 | ||
| NIHSS ≤ 7 days | 0.97 (0.74–1.27) | 0.810 | ||
| NIHSS at 1 year | 1.12 (0.79–1.59) | 0.513 | ||
| NIHSS at 3 months | 1.44 (0.92−2.23) | 0.101 | ||
| MoCA score at 3 months | 0.77 (0.65–0.92) | 0.005* | ||
| DWI lesion volume (cm3) | 1.06 (0.97–1.15) | 0.181 | ||
| DWI lesion on the left side | 1.47 (0.40–5.40) | 0.562 | ||
| Fazekas scale (periventricular + deep white matter) | 0.98 (0.62–1.55) | 0.940 | ||
| Plasma biomarkers | ||||
| Amyloid beta-42 (pg/mL) ≤ 7 days | 1.06 (0.83–1.35) | 0.650 | ||
| Tau (pg/mL) ≤ 7 days | 0.98 (0.91–1.05) | 0.517 | ||
| Amyloid beta-42 (pg/mL) at 3 months | 0.62 (0.42–0.92) | 0.018* | 0.63 (0.41–0.97)† | 0.036* |
| Amyloid beta-40 (pg/mL) at 3 months | 1.10 (0.98–1.21) | 0.118 | ||
| Amyloid beta-42/40 ratio (%) at 3 months | 0.88 (0.78–0.99) | 0.032* | 0.87 (0.76–1.00)† | 0.055 |
| Tau (pg/mL) at 3 months | 0.87 (0.77–0.98) | 0.024* | 0.85 (0.73–0.99)† | 0.031* |
*
P < 0.05,
†
The odds ratio of each plasma biomarker was separately adjusted for MoCA score at 3 months, DWI, diffusion-weighted image; MoCA, Montreal Cognitive Assessment; NIHSS, National Institute of Health Stroke Scale; PSCI, post-stroke cognitive impairment.